Newswise Feature Channel: Pharmaceuticals

New Report Outlines Actionable Strategies to Bridge Gaps Between Access, Affordability and Adherence for Patients

CoverMyMeds — Wed, 05 Mar 2025 05:15:45 EST

Patients continue to face medication access and affordability barriers with 65% experiencing delays in receiving their medications and 54% concerned about costs, according to the 2025 Medication Access Report: From Barriers to Bridges published today by CoverMyMeds.

Bad Bitterness Made Better for Everyone: Global Taste Differences in the Flavor of Medicines

Monell Chemical Senses Center — Tue, 04 Mar 2025 19:20:37 EST

A global Monell Chemical Senses Center examined the bitterness intensity of five medicines and two bitter modifiers in 338 adults of European descent and recent US and Canadian immigrants from Asia, South Asia, and Africa. Bitterness ratings differed by ancestry for two of the five drugs and the effectiveness of some modifiers. Genetic variants also explained some population differences in reaction to bitter tastes.

Rutgers Names Director of Center for Pharmacoepidemiology and Treatment Science at Institute for Health

Rutgers University-New Brunswick — Tue, 04 Mar 2025 09:10:00 EST

Vincent Lo Re, an internationally recognized pharmacoepidemiology researcher, has been named director of the Center for Pharmacoepidemiology and Treatment Science (PETS), a unit of the Rutgers Institute for Health, Health Care Policy and Aging Research (IFH).

Funding the Future of Health: Investment Lessons from GLP-1s

Hevolution Foundation — Fri, 28 Feb 2025 18:15:24 EST

New Target to Thwart Multidrug Resistance in Cancer Treatment

UT Southwestern Medical Center — Tue, 25 Feb 2025 11:05:59 EST

Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, according to a study in preclinical models led by researchers at UT Southwestern Medical Center. The findings, published in Science Advances, could have implications for patients with certain cancers that have KRAS-G12C mutations after resistance to drug therapy develops.

Innovative Research to Advance Oligonucleotide Therapeutics now published in the Journal of Nucleic Acid Therapeutics

Rockland Immunochemicals, Inc — Tue, 25 Feb 2025 11:05:01 EST

Rockland Immunochemicals, Inc. is pleased to announce that Dr. David P. Chimento, Vice President of Research and Development, Amy L. Anderson, Technical Applications Specialist, and Dr. Carl Ascoli, Chief Science Officer, working with Ines Fial, Research Assistant at the Nucleic Acid Therapeutics Accelerator (NATA, Oxford, United Kingdom), have co-authored a peer-reviewed article describing novel technology to demonstrate the safety and efficacy of oligonucleotide therapeutics.

Frontier Scientific Solutions Appoints Kevin Nash as President of European Operations

Frontier Scientific Solutions — Tue, 25 Feb 2025 02:10:22 EST

Frontier Scientific Solutions, a temperature-controlled storage and transportation company exclusively serving the life sciences industry, today announced the appointment of Kevin Nash as President of European Operations.

Expert briefing tomorrow: Drug Costs, Medicare Price Negotiations, PBMs, Drug Ads, and Policy Trends

Johns Hopkins Bloomberg School of Public Health — Mon, 24 Feb 2025 07:30:13 EST

Child ADHD Risk Linked to Mother's Use of Acetaminophen

University of Washington School of Medicine and UW Medicine — Thu, 20 Feb 2025 19:55:24 EST

Acetaminophen metabolites were detected in 20.2% of maternal plasma samples. Children whose mothers had these biomarkers present in their plasma had a 3.15 times higher likelihood of an ADHD diagnosis compared with those without detected exposure.

UC Irvine assistant professor Lauren Albrecht named 2025 Sloan Foundation Research Fellow

University of California, Irvine — Thu, 20 Feb 2025 19:10:29 EST

The Alfred P. Sloan Foundation has named Lauren Albrecht, University of California, Irvine assistant professor of pharmaceutical sciences, a Sloan Research Fellow for her innovative work in cell and chemical biology. She is one of 126 early-career scientists to be recognized this year by the foundation as next-generation leaders.

Emergency Clinicians Increase Prescriptions of Buprenorphine, Effectively Helping Patients Get Started on the Path to Recovery

University of California, Los Angeles (UCLA), Health Sciences — Wed, 19 Feb 2025 11:00:00 EST

In the face of the alarming number of opioid-related deaths in the U.S., there have been national efforts to increase emergency clinician prescribing of buprenorphine, a medication used to treat opioid use disorder.

All Generic Drugs Are Not Equal, Study Finds

Ohio State University — Wed, 19 Feb 2025 08:30:00 EST

Generic drugs manufactured in India are linked to significantly more "severe adverse events" for patients who use them than equivalent drugs produced in the United States, a new study finds. These adverse events included hospitalization, disability, and in a few cases, death.

Frontier Scientific Solutions' Free Trade Zone Advantage Becomes Critical Amid Tariff Changes, Strengthening Life Sciences Supply Chain

Frontier Scientific Solutions — Wed, 19 Feb 2025 04:30:58 EST

As new tariffs on pharmaceutical products and components loom under the Trump administration's proposed trade policies.

Drug Costs, Medicare Price Negotiations, PBMs, Drug Ads, and Policy Trends - Expert Briefing

Johns Hopkins Bloomberg School of Public Health — Tue, 18 Feb 2025 07:25:22 EST

American Society of Anesthesiologists' Center for Perioperative Medicine Launches New Corporate Advisory Council

American Society of Anesthesiologists (ASA) — Thu, 13 Feb 2025 21:25:02 EST

The American Society of Anesthesiologists (ASA) today announced Heron Therapeutics, Solventum, Baxter, Pacira Biosciences and Vertex have joined ASA's Center for Perioperative Medicine (CPMed) Corporate Advisory Council (CAC) to improve patient care and outcomes in perioperative medicine.

Center for Medical Cannabis Research Hosts Statewide Symposium on Emerging Cannabis Science

University of Utah Health — Thu, 13 Feb 2025 21:05:31 EST

Much remains unknown about the risks and benefits of medical cannabis, and as use rates spike, research is urgently needed to understand the full health, social, and even environmental impacts of these medications.

The Molecular Einstein

Empa, Swiss Federal Laboratories for Materials Science and Technology — Thu, 13 Feb 2025 04:10:31 EST

Is it possible to tile a surface with a single shape in such a way that the pattern never repeats itself? In 2022, a mathematical solution to this "einstein problem" was discovered for the first time. Empa researchers have now also found a chemical solution: a molecule that arranges itself into complex, non-repeating patterns on a surface. The resulting aperiodic layer could even exhibit novel physical properties.

Diabetes Can Drive the Evolution of Antibiotic Resistance

University of North Carolina School of Medicine — Wed, 12 Feb 2025 14:00:00 EST

Researchers at the UNC School of Medicine have proven that antibiotic-resistant strains of a harmful bacteria thrive in a diabetic infection environment.

Frontier Scientific Solutions Announces Full-Scale Construction of Largest GMP Temperature-Controlled Facility for Life Sciences in North America at Wilmington International Airport

Frontier Scientific Solutions — Tue, 11 Feb 2025 02:10:45 EST

Frontier Scientific Solutions is excited to announce that construction of its state-of-the-art cGMP temperature-controlled facilities at Wilmington International Airport (ILM) is in full swing with the first vertical structures being installed. This groundbreaking project is set to become the largest GMP temperature-controlled facility fully dedicated to the life sciences sector in North America, further solidifying Wilmington's position as a critical hub for the global life sciences supply chain.

Bleeding Risk with Apixaban and Dabigatran Similar to Aspirin

American College of Physicians (ACP) — Mon, 10 Feb 2025 17:00:00 EST

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found that rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to low-dose aspirin, but rates were higher for rivaroxaban.